State Street Corp Rubius Therapeutics, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.02 - $0.34 $2,955 - $50,248	-147,789 Closed	0 $0
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $668,607 - $5.06 Million	-846,338 Reduced 85.13%	147,789 $126,000
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $5 Million - $12.2 Million	-1,176,410 Reduced 54.2%	994,127 $5.48 Million
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $1.81 Million - $3.31 Million	-186,848 Reduced 7.93%	2,170,537 $21 Million
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $1.46 Million - $2.15 Million	-82,910 Reduced 3.4%	2,357,385 $42.2 Million
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $40 Million - $51.1 Million	1,798,409 Added 280.18%	2,440,295 $59.6 Million
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $199,329 - $795,576	-24,854 Reduced 3.73%	641,886 $17 Million
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $32,659 - $67,404	-7,721 Reduced 1.14%	666,740 $5.06 Million
Q3 2020 Nov 10, 2020	SELL	$4.65 - $6.25 $35,167 - $47,268	-7,563 Reduced 1.11%	674,461 $3.38 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $102,130 - $175,226	25,469 Added 3.88%	682,024 $4.08 Million
Q1 2020 May 11, 2020	BUY	$3.74 - $9.84 $2.46 Million - $6.46 Million	656,555 New	656,555 $2.92 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.